Yves Girerd-Chambaz

USPTO Granted Patents = 8 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 9)

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Paris, FR (2023)
Messimy, FR (2018 - 2024)

Company Filing History:

1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12496335 - Zika virus vaccine (2025-12-16),

2. 11931406 - Flavivirus vaccine (2024-03-19),

3. 11723967 - Zika virus vaccine (2023-08-15),

4. 11690903 - Compositions for booster vaccination against dengue (2023-07-04),

5. 11471521 - Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same (2022-10-18),

6. 11452772 - Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same (2022-09-27),

7. 10946087 - Vaccine compositions against dengue virus diseases (2021-03-16),

8. 9937252 - Induction of cross-reactive cellular response against rhinovirus antigens (2018-04-10),

Title: Yves Girerd-Chambaz: Pioneering Innovator in Vaccine Development

Introduction:

Yves Girerd-Chambaz, a renowned inventor hailing from Messimy, France, is a true visionary in the realm of innovation. With a stellar track record of six patents to his name, Yves has made significant contributions to the field of healthcare through his groundbreaking inventions.

Latest Patents:

Among his latest patents is the revolutionary Zika virus vaccine. This invention entails artificial nucleic acids, polypeptides, and vaccines designed for the treatment and prevention of Zika virus infections and related disorders. Additionally, Yves has developed compositions for booster vaccination against dengue, aimed at inducing a robust neutralizing antibody response in individuals previously vaccinated against different serotypes of the dengue virus.

Career Highlights:

Yves Girerd-Chambaz's career is adorned with remarkable achievements, particularly during his tenure at companies like Sanofi Pasteur Inc. His dedication and innovative prowess have played a pivotal role in advancing vaccine development and combating infectious diseases on a global scale. Yves' relentless pursuit of excellence and commitment to scientific advancement have set him apart as a trailblazer in his field.

Collaborations:

Throughout his illustrious career, Yves has collaborated with esteemed professionals such as Fernando Noriega and Manuel Vangelisti. These partnerships have fostered a culture of creativity and knowledge-sharing, leading to the successful realization of groundbreaking inventions and medical advancements.

Conclusion:

In conclusion, Yves Girerd-Chambaz stands as a beacon of innovation and ingenuity in the realm of healthcare and vaccine development. His unwavering commitment to improving global health outcomes through inventive solutions underscores his status as a true visionary in the field of innovation. Yves' impactful inventions continue to shape the future of healthcare, leaving a lasting legacy in the fight against infectious diseases.

This text is generated by artificial intelligence and may not be accurate.